Comparison of Ardelyx Inc. (ARDX) and MyoKardia Inc. (NASDAQ:MYOK)

Both Ardelyx Inc. (NASDAQ:ARDX) and MyoKardia Inc. (NASDAQ:MYOK) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ardelyx Inc. N/A 580.20 100.42M -1.68 0.00
MyoKardia Inc. 28.23M 75.44 87.35M -1.77 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Ardelyx Inc. and MyoKardia Inc.

Net Margins Return on Equity Return on Assets
Ardelyx Inc. 0.00% -78.4% -51.2%
MyoKardia Inc. -309.42% -18.3% -16.2%

Risk & Volatility

Ardelyx Inc.’s current beta is 1.96 and it happens to be 96.00% more volatile than Standard and Poor’s 500. Competitively, MyoKardia Inc. is 127.00% more volatile than Standard and Poor’s 500, because of the 2.27 beta.

Liquidity

The Current Ratio and a Quick Ratio of Ardelyx Inc. are 7.4 and 7.4. Competitively, MyoKardia Inc. has 8.7 and 8.7 for Current and Quick Ratio. MyoKardia Inc.’s better ability to pay short and long-term obligations than Ardelyx Inc.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for Ardelyx Inc. and MyoKardia Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ardelyx Inc. 0 0 0 0.00
MyoKardia Inc. 0 0 1 3.00

Competitively the consensus price target of MyoKardia Inc. is $85, which is potential 83.90% upside.

Insider & Institutional Ownership

Roughly 84.6% of Ardelyx Inc. shares are held by institutional investors while 81.5% of MyoKardia Inc. are owned by institutional investors. Insiders held roughly 1.1% of Ardelyx Inc.’s shares. Competitively, MyoKardia Inc. has 0.5% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ardelyx Inc. -3.69% -11.58% 20.38% 2.96% -42.57% 74.86%
MyoKardia Inc. -0.21% -5% 21.13% -17.97% 2.19% -2.74%

For the past year Ardelyx Inc. has 74.86% stronger performance while MyoKardia Inc. has -2.74% weaker performance.

Summary

On 6 of the 10 factors MyoKardia Inc. beats Ardelyx Inc.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, a product candidate that is intended to increase cardiac muscle contractility to normal levels in genetic DCM patients through a different mechanism than that of MYK-491; and LUS-1, a product candidate, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart. The company has a strategic collaboration with Sanofi S.A. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.